Type i interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells

Cancer Immunology, Immunotherapy

Volumn 63, Issue 3, 2014, Pages 259-271

  Lim, Joanne Y H ^a   Gerber, Scott A ^a   Murphy, Shawn P ^a,b   Lord, Edith M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

B16 melanoma; CD8+ T cells; CXCR3; Interferon; Radiation therapy

Indexed keywords

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CHEMOKINE CXCL10; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; LYMPHOCYTE COUNT; MAMMARY NEOPLASMS, ANIMAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; NEOPLASM TRANSPLANTATION;

EID: 84894489353     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1506-7     Document Type: Article

References (34)

1. Connell PP, Hellman S (2009) Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res 69:383-392. doi: 10.1158/0008-5472.CAN-07-6871
2. Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, Timmerman RD, McGarry RC (2007) FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 56:229-234. doi: 10.1016/j.lungcan.2006. 12.009
3. Nedzi LA (2008) The implementation of ablative hypofractionated radiotherapy for stereotactic treatments in the brain and body: observations on efficacy and toxicity in clinical practice. Semin Radiat Oncol 18:265-272. doi: 10.1016/j.semradonc.2008.04.009
4. Ritter M (2008) Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol 18:249-256. doi: 10.1016/j.semradonc.2008.04.007
5. Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, Johnson J, Zatcky J, Zelefsky MJ, Fuks Z (2008) High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 71:484-490. doi: 10.1016/j.ijrobp.2007.11.046
6. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM (2005) Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174:7516-7523
7. Lee Y, Auh SL, Wang Y et al (2009) Therapeutic effects of ablative radiation on local tumor require CD8 + T cells: changing strategies for cancer treatment. Blood 114:589-595. doi: 10.1182/blood-2009-02-206870
8. Shiao SL, Coussens LM (2010) The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 15:411-421. doi: 10.1007/s10911-010-9194-9
9. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL (2011) The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res 71:2488-2496. doi: 10.1158/0008-5472.CAN-10-2820
10. Ferrantini M, Capone I, Belardelli F (2007) Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89:884-893. doi: 10.1016/j.biochi.2007.04.006
11. Gresser I, Bourali C, Levy JP, Fontaine-Brouty-Boye D, Thomas MT (1969) Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc Natl Acad Sci USA 63:51-57
12. Picaud S, Bardot B, De Maeyer E, Seif I (2002) Enhanced tumor development in mice lacking a functional type I interferon receptor. J Interferon Cytokine Res 22(4):457-462. doi: 10.1089/10799900252952244
13. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM (2002) Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:119-134
14. Gresser I, Belardelli F (2002) Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 13:111-118
15. Curtsinger JM, Mescher MF (2010) Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 22:333-340. doi: 10.1016/j.coi.2010. 02.013
16. Sorensen EW, Gerber SA, Frelinger JG, Lord EM (2010) IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. J Immunol 184:1858-1866. doi: 10.4049/jimmunol.0903210
17. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM (2008) Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 180:3132-3139
18. Gerber SA, Pober JS (2008) IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells. J Immunol 181:1052-1062
19. Vogel R, Mammeri H, Mallet J (2008) Lentiviral vectors mediate nonimmunosuppressive rapamycin analog-induced production of secreted therapeutic factors in the brain: regulation at the level of transcription and exocytosis. Hum Gene Ther 19:167-178. doi: 10.1089/hum.2007.125
20. Gerber SA, Sorensen EW, Sedlacek AL, Lim JY, Skrombolas D, Frelinger JG, Lord EM (2013) Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology 138:280-292. doi: 10.1111/imm.12037
21. Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM (2013) IFN-gamma mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol. doi: 10.1016/j.ajpath.2013.02.041
22. Brassard DL, Grace MJ, Bordens RW (2002) Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 71:565-581
23. Taylor JL, Grossberg SE (1998) The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol 25:23-29
24. Hong M, Puaux AL, Huang C et al (2011) Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 71:6997-7009. doi: 10.1158/0008-5472.CAN-11-1466
25. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF (2011) Host type I IFN signals are required for antitumor CD8 + T cell responses through CD8{alpha} + dendritic cells. J Exp Med 208:2005-2016. doi: 10.1084/jem.20101159
26. Kline J, Zhang L, Battaglia L, Cohen KS, Gajewski TF (2012) Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol 188:2630-2642. doi: 10.4049/jimmunol.1100845
27. Klemm JD, Schreiber SL, Crabtree GR (1998) Dimerization as a regulatory mechanism in signal transduction. Annu Rev Immunol 16:569-592. doi: 10.1146/annurev.immunol.16.1.569
28. Pollock R, Clackson T (2002) Dimerizer-regulated gene expression. Curr Opin Biotechnol 13:459-467
29. Voloshin T, Voest EE, Shaked Y (2013) The host immunological response to cancer therapy: an emerging concept in tumor biology. Exp Cell Res. doi: 10.1016/j.yexcr.2013.03.007
30. Kondo T, Kobayashi J, Saitoh T, Maruyama K, Ishii KJ, Barber GN, Komatsu K, Akira S, Kawai T (2013) DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci USA 110:2969-2974. doi: 10.1073/pnas.1222694110
31. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M (1994) Functional role of type I and type II interferons in antiviral defense. Science 264:1918-1921
32. Wong LH, Hatzinisiriou I, Devenish RJ, Ralph SJ (1998) IFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs. J Immunol 160:5475-5484
33. Taniguchi T, Takaoka A (2001) A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2:378-386. doi: 10.1038/35073080
34. Rayamajhi M, Humann J, Kearney S, Hill KK, Lenz LL (2010) Antagonistic crosstalk between type I and II interferons and increased host susceptibility to bacterial infections. Virulence 1:418-422. doi: 10.4161/viru.1.5.12787